Predictive Oncology Reports Revenue Surge to $110K, Reduces Net Loss in Latest 10-Q Filing

Predictive Oncology Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2025. The company generated revenue of $110,310, a substantial increase from $4,858 in the same period last year, primarily due to the completion of a tumor-specific 3D model. Despite this revenue growth, the company incurred a net loss of $2,442,873, compared to a net loss of $4,218,843 in the prior year, indicating a reduction in losses year-over-year.

The company's total assets rose to $5,868,251 as of March 31, 2025, up from $4,972,517 at the end of 2024. This increase was driven by a significant rise in cash and cash equivalents, which reached $3,087,588, compared to $611,822 at the end of the previous year. However, total liabilities also increased to $6,014,047, up from $5,175,127, largely due to higher accrued expenses and other liabilities. The accumulated deficit stood at $182,869,144, reflecting ongoing challenges in achieving profitability.

In terms of strategic developments, Predictive Oncology entered into an asset purchase agreement with DeRoyal Industries, selling its Eagan operating segment for $625,000. This segment had been classified as discontinued operations, along with the Birmingham segment, which was previously disposed of. The company also engaged in a share subscription agreement with Renovaro, selling 467,290 unregistered shares for $500,000, although discussions regarding a merger with Renovaro were ultimately discontinued.

Operationally, the company reported a decrease in general and administrative expenses to $1,828,200 from $2,325,664 in the prior year, attributed to reduced professional fees and employee compensation. The workforce reduction has also impacted research and development expenses, which fell to $520,406 from $630,085. As of March 31, 2025, Predictive Oncology had 8,931,621 shares of common stock outstanding, reflecting an increase from 6,666,993 shares at the end of 2024.

Looking ahead, Predictive Oncology faces significant challenges, including the need for additional capital to sustain operations. The company reported negative cash flows from continuing operations of $985,840 for the quarter, and it does not expect to generate sufficient revenue in the near term to meet its operational needs. The management is exploring various funding options, including equity financing and potential asset monetization, but acknowledges that there is substantial doubt about its ability to continue as a going concern within the next year.